Core Viewpoint - Male health issues, particularly erectile dysfunction (ED) and premature ejaculation (PE), significantly impact personal relationships and overall well-being, with a high prevalence among older men in China [1][2]. Group 1: Prevalence and Diagnosis - 41% of Chinese men over 40 experience varying degrees of ED, while 35% suffer from PE, with both conditions often co-occurring [1]. - The diagnosis rates for ED and PE are alarmingly low, at less than 10% and 7% respectively, indicating a gap in medical consultation and awareness [1][2]. Group 2: Treatment Approaches - ED and PE are treatable conditions, with various therapeutic options available, including medication and behavioral therapy [2][3]. - Treatment for ED includes lifestyle changes, oral medications, invasive treatments, and traditional Chinese medicine, while PE treatment encompasses psychological and behavioral therapy, medication, and surgery [3][6]. Group 3: Role of Partners in Treatment - Involving partners in the treatment process is crucial, as it enhances communication and emotional connection, which can lead to better treatment outcomes [3][4]. - The "Male Health and Partner Happiness Manual 2.0" emphasizes the importance of partner involvement in providing psychological support and assisting with lifestyle adjustments [4]. Group 4: Market Dynamics - The market for ED treatment is dominated by long-acting phosphodiesterase type 5 inhibitors, with tadalafil showing significant sales growth, reaching approximately 2.906 billion yuan in 2024 [6][7]. - For PE, dapoxetine is the primary treatment, with over 30 competitors in the market, and sales exceeding 1.3 billion yuan in 2023, primarily through online pharmacies [7][8]. Group 5: Competitive Landscape - The competition in the ED and PE treatment markets is characterized by a mix of original and generic drugs, with online pharmacies becoming a key sales channel [8]. - The market dynamics are shifting due to the inclusion of tadalafil in centralized procurement, impacting the previous dominance of original drugs [7][8].

Group 1 - The core issue of erectile dysfunction (ED) is increasingly recognized, with a prevalence rate of nearly 40% among men over 40 years old in China, and as high as 44.79% among those aged 31-40, indicating a trend towards younger patients [2][3] - The introduction of the domestic drug "Guanai" has significantly reduced the cost of ED treatment, priced at around 5 yuan per tablet, compared to 80-120 yuan for imported original drugs, making it a more accessible option for patients [3][4] - "Guanai" has passed the national consistency evaluation, ensuring its efficacy and safety are on par with original drugs, and is produced using high-purity European imported raw materials [4][5] Group 2 - The drug tadalafil, as a PDE5 inhibitor, offers a prolonged effect lasting up to 36 hours, making it suitable for chronic disease patients, such as those with hypertension and diabetes, thereby improving medication adherence [6] - The company aims to enhance patient willingness to use the drug by implementing a direct-to-consumer (F2C) model and providing online pharmacist services on e-commerce platforms [7][9] - "Guanai" not only focuses on selling medication but also on changing societal perceptions of ED through educational initiatives, helping men understand that ED is a treatable condition [10][12]